Judy Sarungbam1, Narasimhan Agaram2, Sinchun Hwang3, Chao Lu4, Lu Wang2, John Healey5, Meera Hameed2. 1. Department of Pathology, Memorial Sloan Kettering Cancer Center (MSKCC), 1275 York Avenue, New York, NY, 10065, USA. sarungbj@mskcc.org. 2. Department of Pathology, Memorial Sloan Kettering Cancer Center (MSKCC), 1275 York Avenue, New York, NY, 10065, USA. 3. Department of Radiology, Memorial Sloan Kettering Cancer Center (MSKCC), 1275 York Avenue, New York, NY, 10065, USA. 4. Laboratory of Chromatin Biology and Epigenetics, Rockefeller University, 1230 York Avenue, New York, NY, 10065, USA. 5. Department of Orthopedics, Memorial Sloan Kettering Cancer Center (MSKCC), 1275 York Avenue, New York, NY, 10065, USA.
Abstract
OBJECTIVE: Giant cell tumor of bone (GCTB) is a locally aggressive primary bone tumor. Its malignant counterpart is quite rare. Rarely, a conventional GCTB shows marked nuclear atypia, referred to as symplastic/pseudoanaplastic change, which can mimic sarcomatous transformation. Recently, somatic driver mutations of histone H3.3 exclusively in H3F3A have been described in GCTB. We report a series of 9 cases of GCTB with symplastic/pseudoanaplastic change, along with analysis of H3F3A variants. MATERIALS AND METHODS: Nine cases of GCTB with symplastic change were identified. Clinico-radiological features, morphological features, and immunohistochemical stain for Ki-67 stain were reviewed. H3F3A variants were also analyzed using Sanger sequencing. RESULTS: Histologically, conventional giant cell tumor areas with scattered foci of markedly atypical cells were seen in all of the cases and all showed rare if any Ki-67 labeling. One patient had received denosumab treatment and another radiation therapy. Radiological features were characteristic of conventional GCTB. Mutation in H3F3A (p.Gly34Trp [G34W]) was found in 6 of the 7 cases. Clinical follow-up ranged from 6 to 208 months. Local recurrences were seen in 4 cases (44 %). CONCLUSIONS: GCTB with symplastic/pseudoanaplastic change is an uncommon variant of conventional GCTB, which can mimic primary sarcoma or sarcomatous transformation. These tumors possess the same missense mutation in histone H3.3 as conventional GCTB.
OBJECTIVE:Giant cell tumor of bone (GCTB) is a locally aggressive primary bone tumor. Its malignant counterpart is quite rare. Rarely, a conventional GCTB shows marked nuclear atypia, referred to as symplastic/pseudoanaplastic change, which can mimic sarcomatous transformation. Recently, somatic driver mutations of histone H3.3 exclusively in H3F3A have been described in GCTB. We report a series of 9 cases of GCTB with symplastic/pseudoanaplastic change, along with analysis of H3F3A variants. MATERIALS AND METHODS: Nine cases of GCTB with symplastic change were identified. Clinico-radiological features, morphological features, and immunohistochemical stain for Ki-67 stain were reviewed. H3F3A variants were also analyzed using Sanger sequencing. RESULTS: Histologically, conventional giant cell tumor areas with scattered foci of markedly atypical cells were seen in all of the cases and all showed rare if any Ki-67 labeling. One patient had received denosumab treatment and another radiation therapy. Radiological features were characteristic of conventional GCTB. Mutation in H3F3A (p.Gly34Trp [G34W]) was found in 6 of the 7 cases. Clinical follow-up ranged from 6 to 208 months. Local recurrences were seen in 4 cases (44 %). CONCLUSIONS: GCTB with symplastic/pseudoanaplastic change is an uncommon variant of conventional GCTB, which can mimic primary sarcoma or sarcomatous transformation. These tumors possess the same missense mutation in histone H3.3 as conventional GCTB.
Entities:
Keywords:
Giant cell tumor of bone; Symplastic/pseudoanaplastic
Authors: Paul Saiz; Walter Virkus; Patricia Piasecki; Alexander Templeton; Susan Shott; Steven Gitelis Journal: Clin Orthop Relat Res Date: 2004-07 Impact factor: 4.176
Authors: Robert E Turcotte; Jay S Wunder; Marc H Isler; Robert S Bell; Norman Schachar; Bassam A Masri; Guy Moreau; Aileen M Davis Journal: Clin Orthop Relat Res Date: 2002-04 Impact factor: 4.176
Authors: Sam Behjati; Patrick S Tarpey; Nadège Presneau; Susanne Scheipl; Nischalan Pillay; Peter Van Loo; David C Wedge; Susanna L Cooke; Gunes Gundem; Helen Davies; Serena Nik-Zainal; Sancha Martin; Stuart McLaren; Victoria Goodie; Ben Robinson; Adam Butler; Jon W Teague; Dina Halai; Bhavisha Khatri; Ola Myklebost; Daniel Baumhoer; Gernot Jundt; Rifat Hamoudi; Roberto Tirabosco; M Fernanda Amary; P Andrew Futreal; Michael R Stratton; Peter J Campbell; Adrienne M Flanagan Journal: Nat Genet Date: 2013-10-27 Impact factor: 38.330
Authors: Nadège Presneau; Daniel Baumhoer; Sam Behjati; Nischalan Pillay; Patrick Tarpey; Peter J Campbell; Gernot Jundt; Rifat Hamoudi; David C Wedge; Peter Van Loo; A Bassim Hassan; Bhavisha Khatri; Hongtao Ye; Roberto Tirabosco; M Fernanda Amary; Adrienne M Flanagan Journal: J Pathol Clin Res Date: 2015-03-16